Travere Therapeutics
TVTX
169 hedge funds and large institutions have $2.04B invested in Travere Therapeutics in 2021 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 50 reducing their positions, and 16 closing their positions.
144% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 16
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
38% more capital invested
Capital invested by funds: $1.48B → $2.04B (+$566M)
14% more funds holding
Funds holding: 148 → 169 (+21)
7.37% more ownership
Funds ownership: 100.28% → 107.65% (+7.4%)
0% more call options, than puts
Call options by funds: $5.27M | Put options by funds: $5.26M
0% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$42.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$17.7M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$17M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$13.4M |
| 5 |
VA
VR Adviser
New York
|
+$7.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$18.9M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$15.4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$12.5M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.2M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.49M |
TVTX Hedge Fund Activity: Q4 2021 in Review
169 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2021, worth a combined $2.04B — up 38% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new TVTX positions and 16 closed out — a net gain of 23 holders — while 50 added to existing stakes and 50 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $42.3M. The largest seller was Armistice Capital, cutting an estimated $18.9M.
- 169 institutional investors held Travere Therapeutics (TVTX) as of Q4 2021, up from 148 in Q3 2021.
- Funds reported $2.04B of Travere Therapeutics stock for Q4 2021, up 38% quarter-over-quarter.
- 39 funds opened new Travere Therapeutics positions in Q4 2021 and 16 closed out, a net change of +23 holders.
- The largest Travere Therapeutics buyer in Q4 2021 was Goldman Sachs, an estimated $42.3M added.
- The largest Travere Therapeutics seller in Q4 2021 was Armistice Capital, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2021.